Practice

Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

June 19th 2024

By Cameron Santoro

Article

Part 2 of this series dives into the health care system, revealing financial hurdles that limit biosimilar access and ultimately hinder health equity.

British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years

June 18th 2024

By Skylar Jeremias

Article

British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.

New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

June 11th 2024

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.

Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts

June 9th 2024

By Ashley Gallagher

Video

Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.

Switching Patients With IBD to Infliximab, Adalimumab Biosimilars Did Not Impact Efficacy

June 8th 2024

By Deana Ferreri, PhD

Article

Researchers reviewed real-world evidence on the safety and effectiveness of switching from tumor necrosis factor-α inhibitor originators to biosimilars in inflammatory bowel disease (IBD), prompted by mandatory switching policies in most Canadian provinces.

New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching

May 28th 2024

By Skylar Jeremias

Article

A literature review revealed new data demonstrating that biosimilar-to-biosimilar switching is safe and effective.

Biosimilars Account for 23% Market Share, With Wide Uptake Disparities Across Molecules

May 22nd 2024

By Skylar Jeremias

Article

In the IQVIA Use of Medicines in the US 2024 report, biosimilars were found to be large contributors to lower drug costs and drivers of market growth; however, these products account for about 23% of the overall biologics market, showing wide variation in uptake across molecules.

Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD

May 18th 2024

By Deana Ferreri, PhD

Article

A real-world study in Spain on patients with inflammatory bowel disease (IBD) found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.

Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar

April 29th 2024

By Skylar Jeremias

Article

The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

April 24th 2024

By Skylar Jeremias

Article

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.